Drug Trial Radar · NCT06691984
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
707
Actual
Start
Dec 9, 2024
Primary completion
Jan 2, 2029
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
XaluritamigDrug
Short-term IV infusion
AbirateroneDrug
Oral tablets
EnzalutamideDrug
Oral tablets
CabazitaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 53 months
Locations
164 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City of Hope National Medical Center
Duarte, California
Providence Saint Jude Medical Center
Fullerton, California
Cedars Sinai Medical Center
Los Angeles, California
University of California Irvine
Orange, California
University of California San Francisco
San Francisco, California
University of Florida, College of Medicine
Gainesville, Florida
Sylvester Comprehensive Cancer Center-Fox Building
Miami, Florida
AdventHealth Orlando
Orlando, Florida
University of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Louisville Health - James Graham Brown Cancer Center
Louisville, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital, Henry Ford Health Systems
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Washington University
St Louis, Missouri
Yale New Haven Hospital
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University Medical Center Duke Cancer Center
Durham, North Carolina
Sanford Roger Maris Cancer Center
Fargo, North Dakota
Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota
Sarah Cannon Research Institute
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Intermountain Medical Center
Murray, Utah
Virginia Oncology Associates
Norfolk, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Swedish Medical Center
Seattle, Washington
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.